|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV034593780 |
| 003 |
DE-627 |
| 005 |
20230624014237.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180603s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.earlhumdev.2014.10.007
|2 doi
|
| 028 |
5 |
2 |
|a GBVA2015012000026.pica
|
| 035 |
|
|
|a (DE-627)ELV034593780
|
| 035 |
|
|
|a (ELSEVIER)S0378-3782(14)00272-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 618.3/005
|q OCLC
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 100 |
1 |
|
|a Samiee-Zafarghandy, Samira
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Safety of milrinone use in neonatal intensive care units
|
| 264 |
|
1 |
|c 2015
|
| 300 |
|
|
|a 5
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a Milrinone use in the neonatal intensive care unit has increased over the last 10years despite a paucity of published safety data in infants. We sought to determine the safety of milrinone therapy among infants in the neonatal intensive care unit.
|
| 700 |
1 |
|
|a Raman, Sudha R.
|4 oth
|
| 700 |
1 |
|
|a van den Anker, John N.
|4 oth
|
| 700 |
1 |
|
|a McHutchison, Kerstin
|4 oth
|
| 700 |
1 |
|
|a Hornik, Christoph P.
|4 oth
|
| 700 |
1 |
|
|a Clark, Reese H.
|4 oth
|
| 700 |
1 |
|
|a Brian Smith, P.
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
| 773 |
1 |
8 |
|g volume:91
|g year:2015
|g number:1
|g pages:31-35
|g extent:5
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2014.10.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 91
|j 2015
|e 1
|h 31-35
|g 5
|
| 953 |
|
|
|2 045F
|a 610
|